Invest $5,000 into these ASX 200 shares in 2025

Analysts think these shares could be top options for an investment in 2025.

| More on:
Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on.

That's because listed below are three shares that analysts are tipping as top buys for the year ahead.

Here's what you need to know about them:

Domino's Pizza Enterprises Ltd (ASX: DMP)

Analysts at Goldman Sachs are feeling positive about this beaten down pizza chain operator and see it as an ASX 200 share to buy.

After a difficult period, the broker believes that Domino's fortunes could be about to change for the better. This is thanks to its renewed focus on store unit economics. Goldman explains:

We believe that DMP's renewed focus on store unit economics and re-investment to ignite topline growth is rightly placed. While there is still significant progress to be made, we believe that earnings has troughed in FY24 and see a path of improvement through FY25.

The broker has a buy rating and $39.10 price target on its shares. This suggests that upside of 32% is possible from current levels.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Another ASX 200 share that could be a good option for a $5,000 investment is Neuren Pharmaceuticals.

It is a pharmaceuticals company developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

Analysts at Bell Potter are bullish on the company. It sees a lot of potential in the NNZ-2591 asset. It said:

Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.

Bell Potter has a buy rating and $25.00 price target on its shares. This implies potential upside of almost 90% for investors.

Treasury Wine Estates Ltd (ASX: TWE)

A third option for that $5,000 could be Treasury Wine shares. Goldman Sachs is also positive on the wine giant and sees it as an ASX 200 share to buy right now.

The broker believes its shares are undervalued based on its expectation that the company is destined to deliver double-digit earnings growth through to at least 2027. It explains:

Our Buy rating on TWE is premised on accelerating double-digit EPS growth in FY24-27e driven by 1) continued global expansion of Penfolds, especially post the removal of China import tariffs on Australian wine; our recent channel checks suggest positive reception to the returning Australian sourced Penfolds and we expect a ~63pct pre-tariff recovery by 2027.

The broker has a buy rating and $15.20 price target on its shares. This implies potential upside of 31% for investors from current levels.

Motley Fool contributor James Mickleboro has positions in Domino's Pizza Enterprises and Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Domino's Pizza Enterprises and Goldman Sachs Group. The Motley Fool Australia has recommended Domino's Pizza Enterprises and Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Growth Shares

3 monster stocks to hold for the next 3 years

These 3 ASX shares operate in different industries and could be worth holding for long-term growth over the next 3…

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »